ACIU
AC Immune S.A. NASDAQ Listed Sep 23, 2016$2.52
+3.06%
vs $2.45
Mkt Cap $257.0M
52w Low $1.65
37.2% of range
52w High $4.00
50d MA $2.71
200d MA $2.98
P/E (TTM)
—
EV/EBITDA
—
P/B
5.7x
Debt/Equity
0.1x
ROE
—
P/FCF
-3.7x
RSI (14)
52.30
ATR (14)
$0.13
Beta
1.63
50d MA
$2.71
200d MA
$2.98
Avg Volume
286.4K
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Building B · Lausanne, V8 1015 · CH
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | BMO | -0.20 | -0.19 | +5.0% | 3.03 | +0.7% | -3.3% | +3.4% | -1.7% | +2.3% | -1.3% | — |
| Mar 13, 2026 | BMO | -0.19 | -0.18 | +5.3% | 3.00 | -1.3% | +0.7% | +3.6% | +6.1% | -6.9% | -4.5% | — |
| Nov 4, 2025 | BMO | -0.22 | -0.20 | +9.1% | 3.18 | -0.9% | +3.8% | +3.9% | +0.6% | -4.3% | +1.5% | — |
| Aug 5, 2025 | BMO | -0.20 | -0.25 | -25.0% | 2.19 | +0.0% | +11.9% | -11.4% | -4.1% | +2.9% | -3.3% | — |
| Apr 30, 2025 | BMO | -0.22 | -0.21 | +4.5% | 1.70 | +0.0% | +1.8% | -3.5% | +3.0% | -0.6% | -5.3% | — |
| Mar 13, 2025 | BMO | -0.21 | -0.18 | +14.3% | 2.32 | +1.3% | -0.9% | -0.4% | -3.5% | +1.4% | -0.9% | — |
| Nov 5, 2024 | BMO | -0.20 | 0.05 | +125.0% | 2.94 | +4.8% | +10.2% | -4.6% | +5.8% | -2.1% | -0.9% | — |
| Aug 6, 2024 | BMO | 0.42 | -0.25 | -159.5% | 3.49 | +0.9% | +1.1% | -5.4% | +3.0% | -4.7% | +3.4% | — |
| May 13, 2024 | BMO | -0.15 | -0.21 | -40.0% | 2.31 | +46.3% | +42.9% | +8.5% | -2.0% | -2.8% | -6.7% | — |
| Mar 14, 2024 | BMO | -0.07 | -0.06 | +14.3% | 3.70 | +1.9% | -10.0% | +5.1% | +0.0% | -4.0% | -3.0% | — |
| Nov 3, 2023 | BMO | -0.02 | -0.20 | -754.4% | 2.83 | +3.9% | -3.9% | -1.1% | +1.1% | +10.3% | -0.7% | — |
| Aug 4, 2023 | BMO | -0.22 | -0.22 | +0.0% | 2.89 | +6.9% | +3.1% | -1.0% | +5.4% | -2.6% | -0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16 | BTIG | Maintains | Buy → Buy | — | $3.02 | $2.98 | -1.3% | +3.6% | +6.1% | -6.9% | -4.5% | -3.4% |
| Nov 4 | BTIG | Maintains | Buy → Buy | — | $3.18 | $3.15 | -0.9% | +3.8% | +3.9% | +0.6% | -4.3% | +1.5% |
| Sep 8 | BTIG | Maintains | Buy → Buy | — | $2.28 | $2.31 | +1.3% | -3.5% | +0.0% | +9.1% | -0.8% | +2.1% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.73 | $1.72 | -0.6% | -3.5% | +3.0% | -0.6% | -5.3% | +2.5% |
| Apr 3 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $1.88 | $1.82 | -3.2% | -5.9% | -6.2% | -4.2% | -5.0% | +1.3% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.88 | $1.82 | -3.2% | -5.9% | -6.2% | -4.2% | -5.0% | +1.3% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.30 | $2.33 | +1.3% | -0.4% | -3.5% | +1.4% | -0.9% | -2.7% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.55 | $3.53 | -0.6% | -10.1% | -1.6% | +4.1% | -0.9% | +1.5% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.24 | $3.28 | +1.2% | -4.6% | +5.8% | -2.1% | -0.9% | -3.5% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.46 | $3.46 | +0.0% | +4.9% | +1.7% | +0.0% | -0.8% | +1.6% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.33 | $3.30 | -0.9% | +5.1% | +0.0% | -4.0% | -3.0% | -3.4% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.90 | $2.91 | +0.3% | +0.0% | +2.1% | +1.4% | -3.3% | +6.6% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.98 | $3.01 | +1.0% | -1.0% | +5.4% | -2.6% | -0.3% | +1.0% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.40 | $3.11 | -8.5% | -6.5% | -3.1% | -3.9% | -1.7% | -2.1% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.94 | $1.94 | +0.0% | +2.6% | -5.5% | -1.6% | +11.4% | +1.5% |
| Apr 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.21 | $2.18 | -1.4% | -2.7% | +0.9% | +0.5% | -4.1% | -8.1% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.31 | $2.30 | -0.4% | -3.9% | -2.7% | +1.9% | -2.7% | +2.3% |
| Jul 11 | SVB Leerink | Maintains | Outperform → Outperform | — | $3.35 | $3.26 | -2.7% | -1.8% | +0.3% | +4.5% | -2.0% | -0.6% |
| Dec 20 | SVB Leerink | Maintains | Outperform → Outperform | — | $5.02 | $4.94 | -1.6% | +2.6% | -0.4% | +1.2% | +3.9% | -5.2% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.67 | $7.92 | +3.3% | +0.4% | +0.8% | -1.7% | +2.1% | -5.8% |
| Dec 10 | H.C. Wainwright | Maintains | Buy → Buy | — | $8.67 | $8.80 | +1.5% | -3.6% | +2.0% | +2.3% | -2.2% | -3.9% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.67 | $8.80 | +1.5% | -3.6% | +2.0% | +2.3% | -2.2% | -3.9% |
| Feb 1 | UBS | Downgrade | Buy → Neutral | — | $4.12 | $4.04 | -1.9% | -3.4% | -0.3% | -1.3% | +2.0% | -0.8% |
| Nov 13 | Leerink Swann | Maintains | Outperform → Outperform | — | $8.66 | $9.22 | +6.5% | +3.1% | -1.0% | +9.2% | +1.2% | +4.3% |
| Apr 5 | H.C. Wainwright | Maintains | Buy → Buy | — | $10.80 | $10.92 | +1.1% | -11.1% | -6.1% | +1.9% | +6.0% | +0.6% |
| Oct 18 | Credit Suisse | Maintains | Outperform → Outperform | — | $14.43 | $14.83 | +2.8% | +5.3% | -2.9% | +1.4% | +4.8% | -3.2% |
| Oct 18 | Jefferies | Maintains | Buy → Buy | — | $14.43 | $14.83 | +2.8% | +5.3% | -2.9% | +1.4% | +4.8% | -3.2% |
| Oct 18 | Leerink Swann | Maintains | Outperform → Outperform | — | $14.43 | $14.83 | +2.8% | +5.3% | -2.9% | +1.4% | +4.8% | -3.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | Pfeifer AndreaDir/Off | Chief Executive Officer | Sell | 10,000 | $2.79 | $28K | 3,820,288 | +1.81% | +3.53% |
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Wells Fargo & Company/mn | 1,004,284 | $3M | New | Mar 2026 |
| 2 | Millennium Management | 792,657 | $2M | Reduced | Mar 2026 |
| 3 | Renaissance Technologies Llc | 624,367 | $2M | Reduced | Mar 2026 |
| 4 | Arrowstreet Capital, Limited Partnership | 405,658 | $1M | Added | Mar 2026 |
| 5 | Northern Trust Corp | 278,513 | $766K | Reduced | Mar 2026 |
| 6 | Citadel Advisors Llc | 267,233 | $735K | Added | Mar 2026 |
| 7 | Morgan Stanley | 188,690 | $592K | Added | Dec 2025 |
| 8 | Marshall Wace, Llp | 131,458 | $362K | Reduced | Mar 2026 |
| 9 | Dauntless Investment Group, Llc | 107,489 | $296K | Reduced | Mar 2026 |
| 10 | Ubs Group Ag | 101,629 | $279K | Reduced | Mar 2026 |
| 11 | Acadian Asset Management Llc | 96,907 | $266K | Reduced | Mar 2026 |
| 12 | Susquehanna International Group, Llp | 89,262 | $245K | Reduced | Mar 2026 |
| 13 | Two Sigma Investments, Lp | 39,091 | $108K | Reduced | Mar 2026 |
| 14 | China Universal Asset Management Co., Ltd. | 16,362 | $51K | Reduced | Dec 2025 |
| 15 | Bank Of America Corp /de/ | 17,437 | $48K | Added | Mar 2026 |
| 16 | Hrt Financial Lp | 17,276 | $47K | New | Mar 2026 |
| 17 | Jane Street Group, Llc | 10,710 | $34K | New | Dec 2025 |
| 18 | Silverberg Bernstein Capital Management Llc | 10,000 | $28K | — | Mar 2026 |
| 19 | Jpmorgan Chase & Co | 7,640 | $20K | Reduced | Mar 2026 |
| 20 | Banque Cantonale Vaudoise | 7,021 | $19K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 8
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Dimensional U.S. Small Cap ETF | 28,375 | $91K | Jan 2026 |
| 2 | VOYA MULTI-MANAGER INTERNATIONAL SMALL CAP FUND | 10,434 | $33K | Jan 2026 |
| 3 | Dimensional US Core Equity Market ETF | 8,268 | $26K | Jan 2026 |
| 4 | Dimensional U.S. Core Equity 2 ETF | 7,863 | $25K | Jan 2026 |
| 5 | Invesco Nasdaq Biotechnology ETF | 5,590 | $16K | Feb 2026 |
| 6 | AST Small-Cap Equity Portfolio | 4,330 | $14K | Dec 2025 |
| 7 | Dimensional US Vector Equity ETF | 3,399 | $11K | Jan 2026 |
| 8 | Dimensional US Sustainability Core 1 ETF | 2,823 | $9K | Jan 2026 |
Valuation
Market Cap
$257.0M
Enterprise Value
$155.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.12x
P/B
5.66x
P/S
68.72x
P/FCF
-3.68x
EV/EBITDA
—
Shares Out
100.8M
Financials (TTM)
Revenue
$3.7M
Net Income
-$66.2M
EBITDA
-$64.4M
Free Cash Flow
-$67.0M
Op Cash Flow
-$66.1M
EPS Basic
$-0.67
EPS Diluted
$-0.66
EPS Forward
$-0.35
Gross Margin
100.0%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$154.4M
Total Liab.
$109.5M
Total Equity
$44.9M
Cash
$91.5M
LT Debt
$0
Book Value/Sh
$0.45
Debt/Equity
0.10x
Current Ratio
1.02
Quick Ratio
1.02
Returns & Growth
ROE
—
ROA
—
ROIC
-113.9%
Rev Growth YoY
-86.9%
EPS Growth YoY
-31.4%
Price Returns
2W
-5.0%
1M
-12.2%
3M
-9.2%
6M
-11.0%
12M
+55.6%
Technicals
52W High
$4.00
52W Low
$1.65
50d MA
$2.71
200d MA
$2.98
RSI (14)
52.30
ATR (14)
$0.13
Beta
1.63
Avg Volume
286K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$7.00
High
$7.00
Low
$7.00
Median
$7.00
Data updated apr 24, 2026 10:34am
· Source: financialmodelingprep.com